SUMMARYSimpliÿed design methods for obtaining the maximum strain in pipelines crossing active faults proposed by Newmark, Kennedy and Wang have not considered the section deformation of the pipe. In this study, a new simpliÿed method is developed for obtaining the maximum strain in steel pipes crossing faults considering non-linearity of material and geometry of pipe section. It is assumed that the pipe will bend near the fault and the geometry of pipe in the longitudinal direction will change according to a bent deformation. On the other hand, the relation between maximum strain and bent angle has been obtained using a beam-shell hybrid FEM for di erent pipe-fault conditions. The developed method can be used for calculating the maximum strains for fault-crossing steel pipes with di erent angles of crossing both in tension and compression, by considering the deformation of the pipe cross-section.

A new shell finite element method (FEM) model with an equivalent boundary is presented for estimating the response of a buried pipeline under large fault movement. The length of affected pipeline under fault movement is usually too long for a shell-mode calculation because of the limitation of memory and time of computers. In this study, only the pipeline segment near fault is modeled with plastic shell elements to study the local buckling and the large section deformation in pipe. The material property of pipe segment far away from the fault is considered as elastic, and nonlinear spring elements at equivalent boundaries are obtained and applied to two ends of shell model. Compared with the fixed-boundary shell model, the shell model with an equivalent boundary proposed by the study can remarkably reduce the needed memory and calculating time.

No abstract

No abstract

Medications that target programmed cell death protein-1 (PD-1) have proven effective. However, blockade of PD-1/Programmed death-ligand 1(PD-L1) causes immune-related adverse events (irAEs). Characteristics of this irAE include many symptom, low in frequency, and difficulty in prevention. The key to a successful ICI-related treatment lies in the management of irAEs resulting from immune checkpoint inhibitor (ICI) treatment. Although it is difficult to predict irAE, we tried to extract features of irAE expression from analysis of real-world database. This study used data extracted from the Japan Adverse Drug Event Report (JADER) database to assess risk factors associated with serious side effects of irAE, type 1 diabetes (T1DM). The analysis targets were nivolumab, atezolizumab, durvalumab, and pembrolizumab, and the study period was from July 2014 to June 2019. Analysis of Japanese population data confirmed that being women and having melanoma were risk factors for developing ICI-related T1DM. Analysis using this database in combination with information on ICI-related T1DM provides information and guidelines that will help in the safer treatment of ICI in the future.